Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADT effect on PSMA in prostate cancer
NCT03313726Unknown
- Sponsor
- Turku University Hospital
- Start
- Sep 2017
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of relugolix in prostate cancer (PCa) (2 arms), sponsored by Turku University Hospital. Primary endpoint: Maximum Standardised Uptake Value in PSMA-PET at 28 days. Status: unknown.
02
Drugs
relugolix
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03313726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03313726.